Visfatin Serum Levels Predict Mortality in Critically Ill Patients
Table 1
Baseline patient characteristics and visfatin serum measurements.
Parameter
All patients
Nonsepsis
Sepsis
Number
229
87
142
Sex (male/female)
133/96
51/36
82/60
Age median (range) (years)
63 (18–90)
61 (18–85)
64 (20–90)
APACHE II score median (range)
16 (2–43)
14.5 (2–33)
18 (3–43)
ICU days median (range)
7 (1–137)
5 (1–45)
9.5 (1–137)
Death during ICU (%)
60 (26%)
15 (17%)
45 (32%)
Death during follow-up (total) (%)
107 (47%)
31 (36%)
76 (54%)
Mechanical ventilation (%)
157 (69%)
53 (61%)
104 (73%)
Preexisting diabetes (%)
73 (32%)
27 (31%)
46 (32%)
Preexisting cirrhosis (%)
23 (10%)
16 (18%)
7 (5%)
BMI median (range) (m2/kg)
25.9 (15.9–86.5)
25.5 (15.9–53.9)
26.0 (17.1–86.5)
WBC median (range) (×103/μl)
12.8 (0–149)
12.0 (1.8–29.6)
14.0 (0–149)
CRP median (range) (mg/dl)
92 (5–230)
17 (5–230)
153 (5–230)
Procalcitonin median (range) (μg/l)
0.7 (0.03–207.5)
0.2 (0.03–100)
2.3 (0.10–207.5)
Creatinine median (range) (mg/dl)
1.35 (0.1–21.6)
1.0 (0.2–15.0)
1.7 (0.1–21.6)
INR median (range)
1.18 (0.9–13)
1.17 (0.9–6.7)
1.18 (0.9–13)
Log visfatin median (range) (ng/ml)
2.61 (0.78–4.25)
2.51 (0.78–3.89)
2.70 (1.08–4.25)
For quantitative variables, median and range (in parentheses) are given. APACHE: acute physiology and chronic health evaluation; BMI: body mass index; CRP: C-reactive protein; ICU: intensive care unit; INR: international normalized ration; WBC: white blood cell.
